Search for: "S and M Drugs, Inc." Results 1 - 20 of 1,279
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
1 May 2024, 1:18 pm by Melissa Tremblay
Teva Pharmaceuticals, an AKS-based FCA case involving speaker programs sponsored by drug manufacturers, the U.S. [read post]
16 Apr 2024, 8:42 am by Holman
  [M]erely describing the design of an experiment in a ClinicalTrial.Gov disclosure tells a POSA nothing about the obviousness of the study’s eventual result. [read post]
10 Apr 2024, 5:08 pm by jeffreynewmanadmin
“We will not permit pharmaceutical companies to flout price reporting requirements to maintain high drug prices,” said Principal Deputy Attorney General Brian M. [read post]
13 Mar 2024, 1:50 pm by Ben Luftman
By operating a vehicle within the state, drivers have consented to chemical testing to determine BAC or the presence of drugs. [read post]
12 Mar 2024, 12:46 pm by admin
See, e.g., Kidder, Peabody & Co., Inc. v. [read post]
6 Mar 2024, 9:01 pm by renholding
As the release notes, “[m]any commenters provided aggregate cost estimates that did not include certain elements required by the final rules, or included other elements that are not required in the final rules [and it was] difficult to use these cost estimates to quantify the direct costs of the final rules. [read post]
26 Feb 2024, 9:06 pm by News Desk
Grinstead of the Food and Drug Administration’s Office of Criminal Investigations (FDA-OCI) Kansas City Field Office. [read post]
19 Feb 2024, 12:55 pm by Dennis Crouch
  Teva and Apotex, filed Abbreviated New Drug Applications (ANDAs) with the FDA seeking to market generic versions of the $100m+ drug. [read post]
16 Feb 2024, 4:27 am by Allan Blutstein
Jan. 31. 2023) — reversing and remanding district court’s decision and concluding, in relevant part, that the agency failed to establish that the names of companies that supply the government with a drug used for lethal injections qualify as “commercial” information under Exemption 4; and Ctr. for Investigative Reporting v. [read post]
13 Feb 2024, 6:00 am by Public Employment Law Press
– Overpayments for Services Requiring Coordination of Benefits (2022-S-27) The Department of Civil Service contracts with EmblemHealth Plan, Inc. [read post]
13 Feb 2024, 6:00 am by Public Employment Law Press
– Overpayments for Services Requiring Coordination of Benefits (2022-S-27) The Department of Civil Service contracts with EmblemHealth Plan, Inc. [read post]
16 Jan 2024, 9:34 am by Rebecca Tushnet
Unilever United States, Inc., --- F.Supp.3d ----, 2023 WL 6429805, No. 20-cv-1672-AGS-BLM (S.D. [read post]